This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (58) Citing Articles via Google Scholar Google Scholar Articles by Divekar, A. Articles by Ducas, J. Search for Related Content PubMed PubMed Citation Articles by Divekar, A. Articles by Ducas, J.

CLINICAL RESEARCH: PERCUTANEOUS CLOSURE OF ASO

Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder

Abhay Divekar, MBBS^_*,_*, Tidimogo Gaamangwe, MSc, PEng, Nasir Shaikh, MBBS, Michael Raabe, MD and John Ducas, MD

^_* Section of Pediatric Cardiology, Health Sciences Center, Winnipeg, Manitoba, Canada
Section of Adult Cardiology, Health Sciences Center, Winnipeg, Manitoba, Canada
Section of Clinical Engineering, Health Sciences Center, Winnipeg, Manitoba, Canada
Section of Cardiovascular and Thoracic Surgery, Health Sciences Center, Winnipeg, Manitoba, Canada.

Manuscript received October 23, 2004; revised manuscript received December 18, 2004, accepted December 20, 2004.

^_* Reprint requests and correspondence: Dr. Abhay Divekar, FE-241, 685 William Avenue, Winnipeg, Manitoba R3E 0Z2, Canada. (Email: adivekar{at}exchange.hsc.mb.ca).

OBJECTIVES: Amplatzer septal occluder (ASO)-associated cardiac perforation (CP) at our institution prompted this retrospective review.

BACKGROUND: Cardiac perforation is a rare complication after transcatheter atrial septal defect (ASD) closure.

METHODS: To identify CP after transcatheter ASD closure with ASO, cardiac events (CE) describing definite CP, hemopericardium, pericardial effusion, cardiovascular collapse, or sudden death were analyzed. Cardiac events were identified from published literature (MEDLINE), medical device regulating agencies in North America and the European Commission, and AGA Medical Corporation (Golden Valley, Minnesota). Institutional cases were reviewed. Cardiac events were defined as early (pre-discharge) or late (post-discharge).

RESULTS: Twenty-nine CEs were identified. Five were excluded because findings were inconclusive for device-related CP. Ten patients were <18 years of age. Late CEs occurred in 66.6%; 25% presented weeks later (longest, three years). Three deaths were reported. Cardiac perforation occurred predominantly in the anterosuperior atrial walls and/or adjacent aorta.

CONCLUSIONS: Amplatzer septal occluder-associated CP uniquely involves the anterosuperior atrial walls and adjacent aorta. Pathophysiology remains poorly understood.

Abbreviations and Acronyms   ASD = atrial septal defect   ASO = Amplatzer septal occluder   CE = cardiac events   CP = cardiac perforation   FDA = Food and Drug Administration   MAUDE = Manufacturer And User facility Device Experience database   PFO = patent foramen ovale   SBD = stretched balloon diameter   TEE = transesophageal echocardiography

This article has been cited by other articles:

				D. B. McElhinney Patent Foramen Ovale Closure: Let's Keep the Heart in Mind Circulation, June 16, 2009; 119(23): 2967 - 2968. [Full Text] [PDF]

				D. J. Dibardino, D. B. McElhinney, A. K. Kaza, and J. E. Mayer Jr. Analysis of the US Food and Drug Administration Manufacturer and User Facility Device Experience database for adverse events involving Amplatzer septal occluder devices and comparison with the Society of Thoracic Surgery congenital cardiac surgery database. J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1334 - 1341. [Abstract] [Full Text] [PDF]

				K. Yared, A. L. Baggish, J. Solis, R. Durst, J. J. Passeri, I. F. Palacios, and M. H. Picard Echocardiographic Assessment of Percutaneous Patent Foramen Ovale and Atrial Septal Defect Closure Complications Circ Cardiovasc Imaging, March 1, 2009; 2(2): 141 - 149. [Full Text] [PDF]

				S. Windecker and B. Meier Patent Foramen Ovale and Cryptogenic Stroke: To Close or Not to Close? Closure: What Else! Circulation, November 4, 2008; 118(19): 1989 - 1997. [Full Text] [PDF]

				F. Saremi, S. Channual, A. Raney, S. V. Gurudevan, J. Narula, S. Fowler, A. Abolhoda, and J. C. Milliken Imaging of Patent Foramen Ovale with 64-Section Multidetector CT Radiology, November 1, 2008; 249(2): 483 - 492. [Abstract] [Full Text] [PDF]

				A. R. Raghuram, R. Krishnan, S. Kumar, and K. Balamurugan Complications in atrial septal defect device closure Interactive CardioVascular and Thoracic Surgery, February 1, 2008; 7(1): 167 - 169. [Abstract] [Full Text] [PDF]

				T. Walther, C. Binner, A. Rastan, I. Dahnert, N. Doll, V. Falk, F. W. Mohr, and M. Kostelka Surgical atrial septal defect closure after interventional occluder placement: Incidence and outcome J. Thorac. Cardiovasc. Surg., September 1, 2007; 134(3): 731 - 737. [Abstract] [Full Text] [PDF]

				J. E. Lock Device Availability for the Child With Heart Disease J. Am. Coll. Cardiol., June 5, 2007; 49(22): 2222 - 2222. [Full Text] [PDF]

				M. S. Maimon, S. Ratnapalan, A. Do, J. A. Kirsh, G. J. Wilson, and L. N. Benson Cardiac Perforation 6 Weeks After Percutaneous Atrial Septal Defect Repair Using an Amplatzer Septal Occluder Pediatrics, November 1, 2006; 118(5): e1572 - e1575. [Abstract] [Full Text] [PDF]

				M. J. Mullen, D. Hildick-Smith, J. V. De Giovanni, C. Duke, W. S. Hillis, W. L. Morrison, and C. Jux BioSTAR Evaluation STudy (BEST): A Prospective, Multicenter, Phase I Clinical Trial to Evaluate the Feasibility, Efficacy, and Safety of the BioSTAR Bioabsorbable Septal Repair Implant for the Closure of Atrial-Level Shunts Circulation, October 31, 2006; 114(18): 1962 - 1967. [Abstract] [Full Text] [PDF]

				A. W. Nugent, A. Britt, K. Gauvreau, G. E. Piercey, J. E. Lock, and K. J. Jenkins Device Closure Rates of Simple Atrial Septal Defects Optimized by the STARFlex Device J. Am. Coll. Cardiol., August 1, 2006; 48(3): 538 - 544. [Abstract] [Full Text] [PDF]

				C. Jux, H. Bertram, P. Wohlsein, M. Bruegmann, and T. Paul Interventional Atrial Septal Defect Closure Using a Totally Bioresorbable Occluder Matrix: Development and Preclinical Evaluation of the BioSTAR Device J. Am. Coll. Cardiol., July 4, 2006; 48(1): 161 - 169. [Abstract] [Full Text] [PDF]

				M. Cecconi, A. Quarti, F. Bianchini, S. Bucari, C. Costantini, A. Giovagnoni, and G. P. Perna Late Cardiac Perforation After Transcatheter Closure of Patent Foramen Ovale Ann. Thorac. Surg., June 1, 2006; 81(6): e29 - e30. [Abstract] [Full Text] [PDF]

				H.-H. Sauer, K. Ntalakoura, C. Haun, T.-P. Le, and V. Hraska Early Cardiac Perforation After Atrial Septal Defect Closure With the Amplatzer Septal Occluder Ann. Thorac. Surg., June 1, 2006; 81(6): 2312 - 2313. [Abstract] [Full Text] [PDF]

				C. Spies, R. Strasheim, I. Timmermanns, and R. Schraeder Patent foramen ovale closure in patients with cryptogenic thrombo-embolic events using the Cardia PFO occluder Eur. Heart J., February 1, 2006; 27(3): 365 - 371. [Abstract] [Full Text] [PDF]

				M. Schwerzmann and O. Salehian Hazards of percutaneous PFO closure Eur J Echocardiogr, December 1, 2005; 6(6): 393 - 395. [Full Text] [PDF]